[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 262,258
  • Shares Outstanding, K 116,559
  • Annual Sales, $ 6,650 K
  • Annual Income, $ -136,320 K
  • EBIT $ -139 M
  • EBITDA $ -130 M
  • 60-Month Beta 2.13
  • Price/Sales 36.83
  • Price/Cash Flow N/A
  • Price/Book 1.36

Options Overview Details

View History
  • Implied Volatility 150.90% (-6.39%)
  • Historical Volatility 132.71%
  • IV Percentile 20%
  • IV Rank 5.90%
  • IV High 1,257.44% on 11/18/25
  • IV Low 81.57% on 06/04/25
  • Expected Move (DTE 25) 0.59 (26.07%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 464
  • Volume Avg (30-Day) 857
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 6,637
  • Open Int (30-Day) 8,539
  • Expected Range 1.66 to 2.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 6
  • High Estimate $-0.27
  • Low Estimate $-0.30
  • Prior Year $-0.29
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.22 +84.43%
on 04/30/26
2.46 -8.72%
on 05/08/26
+0.88 (+64.23%)
since 04/22/26
3-Month
1.04 +116.35%
on 03/19/26
2.46 -8.72%
on 05/08/26
+0.79 (+54.11%)
since 02/20/26
52-Week
0.91 +147.25%
on 08/11/25
2.46 -8.72%
on 05/08/26
+1.05 (+87.50%)
since 05/22/25

Most Recent Stories

More News
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem...

FATE : 2.25 (+7.14%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.2372 (-1.29%)
BIOA : 16.61 (-0.78%)
LCTX : 1.3000 (-1.52%)
GERN : 1.2800 (+1.59%)
FATE : 2.25 (+7.14%)
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END

CHRS : 1.6100 (+2.55%)
GTBP : 0.4400 (+1.62%)
FATE : 2.25 (+7.14%)
ARTV : 7.87 (-1.50%)
IBRX : 7.22 (-6.72%)
Fate Therapeutics: Q1 Earnings Snapshot

Fate Therapeutics: Q1 Earnings Snapshot

FATE : 2.25 (+7.14%)
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate...

FATE : 2.25 (+7.14%)
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B...

FATE : 2.25 (+7.14%)
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines...

FATE : 2.25 (+7.14%)
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem...

FATE : 2.25 (+7.14%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem...

FATE : 2.25 (+7.14%)
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent...

FATE : 2.25 (+7.14%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 2.58
2nd Resistance Point 2.45
1st Resistance Point 2.35
Last Price 2.25
1st Support Level 2.12
2nd Support Level 1.99
3rd Support Level 1.89

See More

52-Week High 2.46
Last Price 2.25
Fibonacci 61.8% 1.87
Fibonacci 50% 1.69
Fibonacci 38.2% 1.50
52-Week Low 0.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.